Jounce Therapeutics to Announce Third Quarter 2019 Financial Results and Host Conference Call on Thursday, November 7, 2019
October 31 2019 - 8:00AM
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers, today announced that it
will report third quarter 2019 financial results and provide a
corporate update before market open on Thursday, November 7, 2019.
Jounce Therapeutics’ management team will host a live conference
call and webcast at 8:00 a.m. ET.
Conference Call and WebcastTo access the
conference call, please dial (866) 916-3380 (domestic) or (210)
874-7772 (international) and refer to conference ID 3379867. The
live webcast can be accessed under “Events & Presentations” in
the Investors and Media section of the company’s website at
www.jouncetx.com. The webcast will be archived and made available
for replay on the company’s website approximately two hours after
the call and will be available for 30 days thereafter.
About Jounce TherapeuticsJounce Therapeutics,
Inc. is a clinical-stage immunotherapy company dedicated to
transforming the treatment of cancer by developing therapies that
enable the immune system to attack tumors and provide long lasting
benefits to patients through a biomarker-driven approach. Through
the use of its Translational Science Platform, Jounce first focuses
on specific cell types within the human tumor microenvironment to
prioritize targets, and then identifies related biomarkers designed
to match the right immunotherapy to the right patient. Jounce is
developing two clinical-stage programs as well as advancing and
building out its broad and wholly-owned discovery pipeline of
immuno-oncology targets, including those expressed on T-regulatory
cells, macrophages and stromal cells. Jounce’s lead product
candidate, vopratelimab, is a monoclonal antibody that binds to and
activates ICOS and is currently being assessed in a Phase 2
clinical trial. JTX-4014 is a PD-1 inhibitor intended for use in
combination with future pipeline products, and Jounce has completed
enrollment in the JTX-4014 Phase 1 clinical trial. In addition,
Jounce has exclusively licensed worldwide rights to JTX-8064, a
LILRB2 receptor antagonist, to Celgene. For more information,
please visit www.jouncetx.com.
Investor Contact:Komal JoshiJounce
Therapeutics, Inc.(857) 320-2523kjoshi@jouncetx.com
Media Contact:Kathryn MorrisThe Yates
Network914-204-6412kathryn@theyatesnetwork.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Apr 2023 to Apr 2024